Early clinical data indicate a chemopreventive and a chemosensitizing activity of COX-2 inhibitors in breast cancer.76,77 Already initiated or planned clinical trials will further elucidate the significance of COX-2 inhibition in prevention and treatment of breast cancer.77–79. This evidence concerns the gene PTGS2 and breast cancer.